Table 2

Univariate analyses of factors for their association with ALNM

Factor

Unadjusted odds ratio and

95% confidence interval

ALNM negative

(n = 94)

ALNM positive

(n = 116)

P value

Age (yr), mean ± SD

-

55.8 ± 12.4

51.7 ± 13.3

0.020

Age groups (yr)

<50

0.70 (0.40-1.23)

31/94 (33.0%)

48/116 (41.4%)

≥50

63/94 (67.0%)

68/116 (58.6%)

02.12

Tumor size (mm)

T1a (0-5.0)

Reference

6/93 (6.5%)

3/115 (2.6%)

0.001

T1b (5.1-10)

1.54 (0.31-7.72)

13/93 (14.0%)

10/115 (8.7%)

T1c (10.1-20.0)

1.27 (0.29-5.65)

33/93 (35.5%)

21/115 (18.3%)

T2 (20.1-50.0)

3.35 (0.79-14.21)

37/93 (39.8%)

62/115 (53.9%)

T3-T4 > 50

9.50 (1.65-55.0)

4/93 (4.3%)

19/115 (16.5%)

Tumor size >20 mm

3.02 (1.70-5.36)

41/93 (44.1%)

81/115 (70.4%)

<0.001

Histologic grade

1

Reference

19/87 (21.8%)

24/111 (21.6%)

2

0.68 (0.32-1.47)

37/87 (42.5%)

32/111 (28.8%)

0.332

3

1.40 (0.67-2.96)

31/87 (35.6%)

55/111 (49.5%

0.371

Bilateral disease

1.03 (0.37-2.88)

7/92 (7.6%)

9/115 (7.8%)

0.954

Multicentric disease

2.03 (1.07-3.87)

18/93 (19.4%)

38/116 (32.8%)

0.030

Lymphovascular invasion

16.69 (8.30-33.56)

16/91 (17.6%)

89/114 (78.1%)

<0.001

Microcalcification

1.69 (0.93-3.08)

24/90 (26.7%)

43/113 (38.1%)

0.087

Epithelial hyperplasia

2.43 (1.37-4.31)

32/89 (36.0%)

64/111 (57.7%)

0.002

Necrosis

2.12 (1.10-4.08)

17/89 (19.1%)

38/114 (33.3%)

0.024

In situ carcinoma

2.60 (1.32-5.12)

63/92 (68.5%)

96/113 (85.0%)

0.005

Perineural invasion

3.02 (1.70-5.36)

22/91 (24.2%)

50/114 (43.9%)

0.003

Unless otherwise stated, data are expressed as n (%). SD, standard deviation; ALNM, axillary lymph node metastasis

Yenidunya et al. Diagnostic Pathology 2011 6:18   doi:10.1186/1746-1596-6-18